Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
    Contact Us
  • Affiliated Brands
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    Visit JONS
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
    Visit TON
  • Healthcare Providers
  • Contribute

Cancer, Clearly

Cancer, Clearly
Making complex cancer conversations clearer, calmer, and more human.
Featuring oncologists, researchers, advocates, caregivers, and survivors discussing the realities of modern cancer care with honesty, empathy, and clarity.
Delving Beyond the Infusion With Dr. Jennifer Brown and the AMPLIFY Trial’s Oral Breakthrough for CLL
Episode 1
Delving Beyond the Infusion With Dr. Jennifer Brown and the AMPLIFY Trial’s Oral Breakthrough for CLL
In this episode, we sit down with Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, to unpack the AMPLIFY trial that is reshaping chronic lymphocytic leukemia (CLL) treatment. She explains how this new oral combination isn’t just effective but patient-friendly, cutting down on complexity and paving the way for more accessible care. Tune in to hear how this breakthrough is setting the stage for the future of CLL therapy. Listen Now  ›